Overview of HPB Panalab

Property	Description
Active ingredient	Finasteride
Form	Tablet (Film-coated)
Pharmacological class	5-alpha reductase inhibitor (5-ARI)
General purpose	To modulate androgen-driven physiological processes
Origin	Synthetic aza-steroid compound

Defining HPB Panalab: Composition and Pharmacological Identity

HPB Panalab is a prescription-only medicinal product containing the single active ingredient Finasteride. This compound is classified within the pharmacological class of 5-alpha reductase inhibitors (5-ARIs).

Finasteride is a synthetic compound, specifically an aza-steroid derivative, developed for its highly targeted action. The classification as a 5-ARI confirms its unique mechanism, which focuses on enzyme inhibition rather than broader hormonal interaction. Its use is clinically recognized for addressing conditions where hormonal modulation is necessary, positioning it as a key intervention in this therapeutic area.

Composition and Physical Form

The medicine is supplied as an oral agent in the form of tablets, typically film-coated tablets.

The core composition consists of Finasteride combined with inactive solid excipients required for the tablet matrix and coating. This formulation is designed for oral administration, ensuring the consistent, systemic delivery of Finasteride throughout the body, as required for its therapeutic effect. The consistent delivery provided by the standardized tablet form is a defining characteristic, suitable for the adult male patient group.

How HPB Panalab Generally Works (Core Principle)

HPB Panalab’s core principle involves the selective inhibition of the Type II 5-alpha reductase enzyme.

This enzyme blocking action prevents the metabolic conversion of testosterone into the more potent hormone, dihydrotestosterone (DHT). The resulting DHT reduction is the basis of the medicine's general purpose: to modulate physiological processes driven by the action of this potent androgen. The efficacy of this hormone reduction approach is recognized in medical literature concerning androgen-driven conditions.

Regulatory References

What side effects are possible with HPB Panalab?

Possible Side Effects and Safety Information

The safety profile for HPB Panalab (Finasteride) is organized by regulatory authorities based on system-organ class and frequency of occurrence, as documented in official prescribing information.

Frequency-Classified Adverse Reactions

The most frequent adverse reactions primarily involve the reproductive system. The following effects are officially classified:

Common (may affect up to 1 in 10 men): Decreased libido (sexual drive), erectile dysfunction (impotence), and decreased volume of ejaculate.
Uncommon (may affect up to 1 in 100 men): Ejaculation disorder, depressed mood, rash, and breast enlargement (gynaecomastia) or tenderness.
Not Known (frequency cannot be estimated): Reports include testicular pain, male infertility, palpitation, anxiety, suicidal ideation, and male breast cancer.

Serious and Contextual Safety Notes

Official labeling addresses several important safety considerations. Post-marketing data has included reports of the persistence of sexual dysfunction (decreased libido, erectile dysfunction, ejaculation disorder) after the medicine has been discontinued. Severe hypersensitivity reactions, such as angioedema (swelling of the face, tongue, and throat), have also been reported.

For specific populations, pregnant women should not handle crushed or broken tablets due to the potential risk to a male fetus. The medicine is not indicated for use in women or in pediatric patients (under 18 years). Clinically, the medicine causes a reduction in Prostate Specific Antigen (PSA) levels, which must be considered when evaluating results for prostate cancer screening, as defined in regulatory documents.

Overdose and Emergency Response

HPB Panalab Overdose and when to seek help

The official regulatory documentation for HPB Panalab provides specific statements regarding overdosage and the mandatory actions required in an emergency.

Official Overdose Profile

The regulatory label is based on documented clinical trial data where the active ingredient, Finasteride, was administered at notably high levels. This includes single doses up to 400 mg and continuous multiple daily doses reaching 80 mg over a three-month period. In these documented exposures, regulatory authorities note that no specific adverse effects were observed in the individuals. Consistent with this limited clinical experience, the labeling states that no specific treatment can be recommended for an acute overdosage. Therefore, professional management of any ingestion suspected to be an overdosage is primarily considered symptomatic and supportive.

Mandatory Emergency Action

Government guidance requires the seeking of immediate medical attention when severe symptoms occur. Emergency services (911) must be contacted without delay if the affected person shows signs such as collapse, has a seizure, experiences severe trouble breathing, or cannot be awakened. Additionally, the Poison Control Helpline must be contacted immediately following any suspected high-dose exposure or accidental ingestion. These mandated actions focus on addressing general life-threatening instability.

Therapeutic Uses of HPB Panalab

What HPB Panalab Treats: Main Uses and Benefits

HPB Panalab addresses two distinct therapeutic domains in adult men, relevant for symptom relief and managing symptoms in conditions where physiological processes are changing within specific clinical scenarios.

Enlarged Prostate and Lower Urinary Tract Symptoms (LUTS)

This therapeutic domain is relevant for adult men experiencing symptoms linked to organ-specific functional stress caused by benign enlargement of the prostate gland. This medication is commonly used to help with managing the cluster of obstructive urinary symptoms, such as difficulty starting the stream, a weak urine flow, and nocturia (frequent nighttime urination). The long-term benefit assists with managing symptoms related to physical discomfort and may support a more steady urinary flow and may assist with maintaining functional stability during symptomatic periods.

Male Pattern Hair Loss and Hair Density Maintenance

The medication is commonly used to help with the progressive, hereditary condition known as androgenetic alopecia in men. It is applied to ease symptoms that create noticeable physiological strain by targeting the progressive thinning seen in the characteristic areas, typically the crown (vertex) and anterior mid-scalp. The primary benefit is that it supports the patient during episodes of heightened discomfort by addressing symptoms associated with hair loss, which may help patients cope more steadily with symptom fluctuations by contributing to visible hair density and coverage over time.

Quick Fact: Therapeutic Context

HPB Panalab is commonly used across conditions presenting with periods of heightened symptoms in urology and dermatology, specifically Benign Prostatic Hyperplasia (BPH) and Male Pattern Hair Loss.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

HPB Panalab is a medicine exclusively approved for use in adult men aged 18 years and older. Regulatory authorities strictly define eligibility based on gender, age, and pre-existing health status, classifying specific groups for prohibition or restricted use.

Eligibility Status	Population/Condition
Contraindicated (Must Not Use)	Women (especially when pregnant or potentially pregnant), Children and Adolescents (Safety and efficacy not established in this age group), Hypersensitivity to the active substance or any excipient, and patients with certain hereditary problems of sugar intolerance.
Use with Caution/Restriction	Hepatic Impairment (Caution is advised, as the medicine is extensively metabolized in the liver), Men whose sexual partner is pregnant (Exposure minimization is advised), Men with certain risks related to high-grade prostate cancer (requires careful evaluation).
Use Established (No Dose Adjustment)	Geriatric Patients (ge 65 years) and patients with Renal Insufficiency (Chronic kidney impairment).

The official profile confirms the medicine is not indicated for women, due to the documented potential for risk to a male fetus if a pregnant woman is exposed. Use in the pediatric population is strictly contraindicated because safety and effectiveness are not established below the age of 18.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents indicate that the active ingredient in HPB Panalab, finasteride, does not appear to affect the cytochrome P450-linked drug-metabolizing enzyme system. This suggests a low potential for complex pharmacokinetic interactions when co-administered with other medicines that utilize this enzyme system.

Official Interaction Statements

Clinical studies have specifically investigated the concurrent use of finasteride with a defined set of other medicinal products. These regulatory studies determined that no clinically significant drug interactions were identified when finasteride was co-administered with the following agents:

Specific Interacting Medicines Tested	Interaction Classification
Digoxin, Propranolol, Warfarin, Theophylline
Antipyrine, Glibenclamide	No Clinically Significant Interaction Found

Interaction-Related Constraints

Based on the available regulatory information, there are no broad restrictions or mandatory timing separation requirements specified for the general concurrent use of this product with other prescription medicines. Furthermore, the official label does not document any population-specific interaction notes, such as specific considerations for patients with renal or hepatic impairment related to drug interactions.

The regulatory profile is structured by these specific tested compounds, establishing a basis for the product's overall low interaction risk as reported in official documentation.

Mechanism of Action

Enzyme Inhibition and DHT Suppression

The action of the active ingredient operates via selective competitive inhibition of the 5-alpha reductase enzyme, specifically targeting the Type II and Type III isoenzymes. This enzyme is the primary molecular catalyst that facilitates the conversion of Testosterone into the more potent androgen, Dihydrotestosterone (DHT). By binding to the enzyme's active site, the molecule blocks this biochemical reaction, causing a sustained reduction in the amount of DHT available systemically and within androgen-sensitive target cells.

Mechanistic Cascade to Tissue Regression

This molecular suppression of DHT initiates a critical downstream mechanistic cascade. The resulting low concentrations of the powerful ligand lead to a sustained reduction in the activation of nuclear androgen receptors, which regulate cellular maintenance and growth processes. The consequence of this reduced pro-growth signaling is a physiological change involving cellular regression or atrophy, leading to an alteration in the size of the androgen-sensitive tissues over time.

Dosage and Administration Information

How to Use HPB Panalab

HPB Panalab is an oral medicine administered strictly according to established protocols for its specific uses. The medicine is formulated as a film-coated tablet and is consistently taken once daily. The required strength and total duration of use depend on the condition being managed, but both regimens are based on long-term administration to maintain the intended pharmacological effect.

Official Administration Pattern

Feature	Official Instruction
Route of Administration	Oral (by mouth)
Dosing Frequency	Once per day
Relation to Meals	May be taken with or without food
Swallowing Technique	The tablet must be swallowed whole
Duration Principle	Continued daily use is necessary for sustained action

The tablets should not be broken, crushed, or chewed, as per standard administration guidelines. Administration may occur at any time of day, but consistently taking the dose at the same time daily is typically advised.

Indication-Specific Dosing

Official labeling defines two distinct adult dosing strengths for this compound:

For Benign Prostatic Hyperplasia (BPH): The standard administration is 5 mg once daily. A treatment course of six months or more may be required to properly determine the full effect.
For Male Pattern Hair Loss: The standard administration is 1 mg once daily. A minimum of three months of continuous daily use is generally required before a clear benefit can be assessed.

No dosage adjustment is required for older adults or patients with renal impairment, and the medicine is not indicated for use in pediatric patients.

Recent Clinical Evidence

HPB Panalab: Recent Clinical Evidence

Clinical research and observational studies concerning HPB Panalab primarily focus on its observed effects in relation to specific metabolic pathways. Findings from early-phase trials have suggested that use of HPB Panalab was associated with certain changes in markers relevant to hepatic and pancreatic function.

Efficacy Findings

Research evidence has investigated the compound's impact on systemic glucose regulation. Certain studies have reported an observed correlation with reductions in A1C levels, a key measure of long-term blood sugar control, in specific adult populations.

Furthermore, limited data from smaller studies noted an association with stable body weight or, in some cases, modest weight reduction when compared to baseline measurements in the studied cohorts. This effect requires further investigation in large-scale, comparative trials.

Ongoing Research and Context

The full clinical utility of HPB Panalab continues to be the subject of ongoing research. Current investigation seeks to clarify the compound's role in the context of broader metabolic syndrome indicators. It is noted that findings from early research consistently report that the compound is commonly referenced in initial treatment protocols for managing elevated blood sugar, especially in adults. However, the exact long-term clinical benefits, safety profile, and efficacy across diverse patient demographics remain subjects of continued analysis and comprehensive study.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about HPB Panalab (FAQ)

Q: Is HPB Panalab a cure or a treatment for the condition?

According to official product information, HPB Panalab is classified as a treatment intended for the long-term management of its approved conditions. The full beneficial effect is associated with continuous, sustained administration.

Q: Can HPB Panalab affect the results of blood tests?

Official regulatory documents confirm that HPB Panalab can cause a reduction in Prostate Specific Antigen (PSA) levels. Healthcare providers must consider this change when interpreting the results of PSA screening tests.

Q: Is HPB Panalab known to be habit-forming?

Based on regulatory classification, the active ingredient in HPB Panalab is not currently listed as a controlled substance. This suggests that it is not considered habit-forming.

Q: What should be avoided when using HPB Panalab?

Official guidance indicates HPB Panalab is contraindicated if there is a known hypersensitivity (a severe allergic reaction) to the active ingredient. Furthermore, the film-coated tablets should not be crushed or broken. Official warnings state that pregnant women must not handle damaged tablets due to the potential risk to a male fetus.

Q: Can HPB Panalab be used during pregnancy or while breastfeeding (general classification)?

HPB Panalab is contraindicated, meaning it must not be used by women, particularly those who are pregnant or may become pregnant. This is because the medicine poses a potential risk to a developing male fetus. Its safety for use while breastfeeding has also not been established by official sources.

Q: Does the time of day I take HPB Panalab matter?

Regulatory information states that you may take HPB Panalab at any time of day. However, regulatory guidelines indicate that taking the dose at approximately the same time each day can help maintain its therapeutic effect.

Q: What is the typical timeframe before a doctor might review the treatment?

Studies indicate that the full beneficial effect of the medicine requires continuous daily use for a sustained period. Official regulatory guidelines suggest a timeframe of at least three to six months before the benefit can be accurately assessed by a healthcare provider.

Q: How quickly should I expect to see an effect from HPB Panalab?

While the drug starts its underlying biochemical process (enzyme suppression) relatively quickly, the desired clinical effects require time to develop. Continuous administration for several months is necessary before the results can be properly assessed.

Q: What happens if I forget to take a dose of HPB Panalab?

If a dose of HPB Panalab is missed, official instructions indicate that patients should not take an extra tablet to compensate. Patients should simply resume the regular dosing schedule by taking the next dose at the usual time.

Q: Can HPB Panalab be taken with common over-the-counter pain relievers?

Official drug interaction studies are primarily focused on prescription medicines. While specific testing with common over-the-counter pain relievers is generally not documented, HPB Panalab has a low potential for complex drug interactions, as it does not affect the major drug-metabolizing enzyme system.

Q: Is HPB Panalab safe to use if I have liver problems?

Because the medicine is extensively metabolized in the liver, caution is advised for patients with existing hepatic impairment (liver problems). However, official documentation confirms that no dosage adjustment is typically required for patients with general hepatic insufficiency.

Q: Can HPB Panalab affect driving or operating machinery?

Regulatory documents indicate that HPB Panalab is not expected to affect an individual's ability to drive a vehicle or safely operate machinery.

Q: Can HPB Panalab cause weight changes?

Based on the official regulatory documentation, weight changes are not listed among the commonly or uncommonly reported side effects. Early clinical studies often noted an association with stable body weight during treatment.

Q: Is HPB Panalab safe for use if I have severe hypersensitivity to any of the ingredients?

If a patient has a known hypersensitivity (a severe allergic reaction) to the active substance or any other ingredient in the tablet, its use is considered a contraindication. This means the medicine must not be used in such cases, as stated in the contraindications.

Q: Does HPB Panalab interact with herbal supplements like St. John's Wort?

Specific drug interaction studies documented in the official product label generally focus on prescription medicines, and interactions with herbal supplements like St. John's Wort are not typically documented. The medicine is reported to have a low potential for complex pharmacokinetic interactions.

Q: How can I tell if HPB Panalab is working for my condition (non-clinical expectations)?

The medicine works by causing a gradual physiological change, which requires continuous use over a sustained period. Official studies state that it typically takes three to six months before the effects can be properly assessed by a healthcare provider.

Q: Can HPB Panalab be stopped suddenly, or does it require a gradual reduction?

Official regulatory documents do not typically specify a requirement for a gradual reduction, or tapering, of the dose. The effects of the drug are generally known to wear off slowly after it is discontinued.

Q: What are the signs of a serious, but rare, side effect of HPB Panalab?

Serious, but rare, reactions mentioned in official labeling include signs of severe hypersensitivity, such as swelling of the face, lips, tongue, or throat (angioedema). These signs are reported to indicate a need for urgent medical assistance.

Q: How is HPB Panalab typically supplied (e.g., packaging size)?

HPB Panalab is typically supplied as film-coated tablets for oral use. These are usually packaged in standard dispensing bottles or blister packs containing quantities such as 30 or 90 tablets, based on the duration of the prescribed therapy.

Q: What is the process for safe disposal of unused or expired HPB Panalab?

Official guidance requires the use of a dedicated drug take-back program or pharmacist guidance for disposal, as disposal in the household trash or by flushing is usually prohibited.

Q: Does taking HPB Panalab for a long period change its effects?

Post-marketing data has included reports concerning the potential for persistence of sexual dysfunction (such as decreased sexual drive or erectile dysfunction) in some individuals even after the medicine has been stopped.

Q: Does HPB Panalab cause sensitivity to sunlight?

Increased sensitivity to sunlight, known as photosensitivity, is not listed among the common or uncommon dermatological side effects described in the official regulatory documentation for the medicine.

How should HPB Panalab be stored and disposed of?

Storage and Disposal Requirements

HPB Panalab (Finasteride tablets) must be stored under specific environmental conditions to maintain stability and comply with regulatory standards.

Storage Conditions

Requirement	Official Stipulation
Temperature	Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Protection	Protect from light and moisture.
Container	Keep in the original container, tightly closed.

Handling and Safety

The medication must be kept strictly out of the reach of children. A mandatory handling restriction is in place: women who are or may be pregnant must not handle crushed or broken tablets. The film-coated tablets should not be broken for administration.

Disposal Protocol

Unused or expired HPB Panalab must be disposed of according to local regulations. Disposal via household trash or wastewater (flushing down toilets or sinks) is generally prohibited. Patients should utilize a formal drug take-back program or follow guidance from a pharmacist for discarding the product safely.

HPB Panalab